Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Assessment of acute bone loading in humans using [18F]NaF PET/MRI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. 18F FDG-PET/CT has poor diagnostic accuracy in diagnosing shoulder PJI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Different preprocessing strategies lead to different conclusions: A [11C]DASB-PET reproducibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Towards selective CNS PET imaging of the 5-HT7 receptor system: Past, present and future

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: The serotonin receptor subtype 2A antagonist (5-HT2AR) (R)-[18F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT2ARs. It displays a very similar selectivity profile as [11C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT2AR. As [11C]MDL 100907, (R)-[18F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT2AR binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[18F]MH.MZ PET to image and quantify the 5-HT2AR in the human brain in vivo.

METHODS: Nine healthy volunteers underwent (R)-[18F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time-activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[18F]MH.MZ 5-HT2AR binding, and performance of different kinetic modeling approaches.

RESULTS: Highest uptake was determined in 5-HT2AR rich regions with a BPND of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[18F]MH.MZ binding conformed to the known distribution of 5-HT2AR and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100-110 min.

CONCLUSION: (R)-[18F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT2AR system in humans. In comparison with [11C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[18F]MH.MZ. We believe that (R)-[18F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT2AR system.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Nuclear Medicine and Molecular Imaging
Vol/bind47
Udgave nummer2
Sider (fra-til)355-365
Antal sider11
ISSN1619-7070
DOI
StatusUdgivet - feb. 2020

ID: 59790283